loading page

Identification of cucurbitacin IIb as a potential EGFR tyrosine kinase inhibitor
  • +1
  • Tiehua Zhang,
  • Yuan Liang,
  • Jie Zhang,
  • Zhengyi Wei
Tiehua Zhang
Jilin University
Author Profile
Yuan Liang
Jilin University
Author Profile
Jie Zhang
Jilin University
Author Profile
Zhengyi Wei
Jilin Academy of Agricultural Sciences
Author Profile

Abstract

Background and Purpose: Epidermal growth factor receptor (EGFR) is considered as a valid target in the clinical trials of anticancer therapy and tyrosine kinase inhibitors (TKIs) of EGFR are approved for cancer treatments. Experimental Approach: A549 cells proliferation, apoptosis, and cycle analysis were measured by MTT, annexin V-FITC apoptosis, and PI-staining assay, respectively. Meanwhile, the accumulation levels of the gene and protein were carried out by real-time quantitative PCR and western blotting assays. The inhibiting effect of CuIIb against the phosphorylation level of the EGFR protein was detected by homogeneous time-resolved fluorescence (HTRF) analysis. Based on molecular docking, the binding interaction of CuIIb with EGFR was evaluated. Key Results: CuIIb was confirmed to exhibited the proliferation inhibitory activity in A549 cells. CuIIb induced apoptosis via STAT3 pathway and arrested the cell cycle in G2/M phase. HTRF analysis demonstrated the kinase activity of EGFR was inhibited by CuIIb. The results of molecular docking suggest that the CuIIb-EGFR binding fundamentally depends on the contribution of both hydrophobic and hydrogen-bonding interactions. Conclusion and Implications: CuIIb was capable of suppressing the signal transmitting of the EGFR/MAPK pathway by severely reduced the amounts of the most participants in the pathway and inhibited the activation thereof, thus suppression of EGFR/MAPK signaling pathway was responsible to the apoptosis and cell cycle arrest. In addition, CuIIb may serve as a potential EGFR TKI.